Protein drug target activation mapping to change the paradigm in precision medicine based cancer therapy
Avant Diagnostics (whose corporate name has been changed to Theralink Technologies, Inc.) on Theralink’s Reverse
Phase Protein Array (RPPA) Technology.
Theralink may enable clear decision making for an individual patient’s cancer treatment using protein biomarkers.
FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
Theralink biopharma services will help drug companies accelerate their drug discovery programs.
Our RPPA technology can evaluate over 600 different protein and phosphoprotein targets
Our company builds upon 1000+ peer-reviewed publications using the RPPA technology to advance precision medicine
Our services are supported by seven patents covering the RPPA technology and the phosphoproteome